【24h】

Review on Thalassemia

机译:地中海贫血评论

获取原文
       

摘要

Thalassemia was clinically described almost 100 years ago and treatment of this genetic disease has seen a great progress during this period. DNA-based diagnosis proved the molecular basis of the disease and clarified the variable clinical picture. It also laid path for modern methods of carrier identification and prevention through DNA-based prenatal diagnosis. All aspects of supportive care, like safer blood supply, regular transfusions, monitoring of iron overload, parenteral as well as oral chelation, and other therapies, helped to prolong life and improve the quality of life of the patients. Many advances are also seen in allogenic bone marrow transplantation, which is the only curative therapy. Recent research has mainly focused on studying thalassemia at the basic science level, which resulted in the identification of unknown mechanisms leading to anemia and enabling the development of novel therapies which helps to improve the treatment of, and possibly cure the disease. Various pathways involving activin receptors, JAK2 inhibitors, heat shock proteins and macrophage targeted therapy, etc are under study or are currently undergoing clinical trials for treating thalassemia. Novel genetic therapies are being investigated.
机译:地中海贫血症的临床描述已近100年,在此期间,这种遗传性疾病的治疗取得了长足的进步。基于DNA的诊断证明了该疾病的分子基础,并阐明了可变的临床情况。它还通过基于DNA的产前诊断为现代载体识别和预防方法奠定了道路。支持性护理的各个方面,例如更安全的血液供应,定期输血,监测铁超载,肠胃外以及口服螯合剂和其他疗法,有助于延长患者的生命并改善其生活质量。同种异体骨髓移植是唯一的治疗方法,也有许多进展。最近的研究主要集中在基础科学水平上对地中海贫血的研究,这导致了导致贫血的未知机制的识别,并使新疗法的发展成为可能,该疗法有助于改善疾病的治疗方法,甚至可能治愈该疾病。涉及激活素受体,JAK2抑制剂,热休克蛋白和巨噬细胞靶向疗法等的各种途径正在研究中,或者正在接受治疗地中海贫血的临床试验。正在研究新的基因疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号